Related Experiment Video
Updated: Nov 9, 2025
07:41
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
2.1K
Pulmonary vasodilator use in continuous-flow left ventricular assist device management
Preethi Pirlamarla1, Eduardo Rame1, Charles Hoopes2
1Advanced Heart Failure and Transplant Cardiology, Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Annals of Translational Medicine
|April 14, 2021
Summary
Pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) requires careful management. This review explores pharmacologic strategies for PH post-left ventricular assist device implantation.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Medical Devices
Background:
- Pulmonary hypertension (PH) from left heart disease is common, particularly in heart failure with reduced ejection fraction (HFrEF).
- PH-HFrEF is linked to reduced function, increased mortality, and can progress to right heart failure.
- Management challenges exist, especially regarding the precapillary component of PH after interventions.
Purpose of the Study:
- To review the pharmacologic management of pulmonary hypertension (PH) in patients after continuous-flow left ventricular assist device (cfLVAD) implantation.
- To address the undefined role of pulmonary vasodilators for the precapillary PH component post-cfLVAD.
Main Methods:
- Review of existing literature on PH management in HFrEF.
- Analysis of outcomes following cfLVAD implantation in patients with PH.
- Discussion of pharmacologic strategies for PH post-cfLVAD.
Main Results:
- Left ventricular assist device implantation significantly improves pulmonary artery pressures by unloading the left ventricle.
- The efficacy and safety of pulmonary vasodilators for residual precapillary PH post-cfLVAD remain unclear.
- Current guidelines do not clearly define the role of pulmonary vasodilators in this specific patient population.
Conclusions:
- Continuous-flow left ventricular assist device implantation offers significant hemodynamic benefits for PH-HFrEF.
- Further research is needed to establish optimal pharmacologic strategies for managing precapillary PH after cfLVAD.
- Careful patient selection and ongoing monitoring are crucial for managing PH in advanced HFrEF.
Related Concept Videos
01:30Heart Failure V: Medical Management
70
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
70
01:22Heart Failure VI: Adjunct Therapies
80
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
80
01:26Mitral Stenosis III: Medical Management
90
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
90
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
125
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
125
01:26COPD: Management Using Bronchodilators and Corticosteroids
522
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
522